Generation of Her-2/neu vaccine utilizing idiotypic network cascade

Smarajit Pal; Asim Saha; Kartik Mohanty; Palash Mallick; Sunil K. Chatterjee; Kenneth A. Foon; Malaya Bhattacharya-Chatterjee

doi:10.4161/cbt.6.12.4967

Generation of Her-2/neu vaccine utilizing idiotypic network cascade

Smarajit Pal, Asim Saha, Kartik Mohanty, Palash Mallick, Sunil K. Chatterjee, Kenneth A. Foon, Malaya Bhattacharya-Chatterjee

Pediatrics - Blood/Marrow Transplant

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Our goal is to apply an anti-idiotype (Id) antibody based vaccine approach for the treatment of Her-2/neu-positive human cancer. Amplification and/or overexpression of Her-2/neu occur in multiple human malignancies and are associated with poor prognosis. The Her-2/neu proto-oncogene is a suitable target for cancer immunotherapy. Our strategy is active specific immunotherapy in which patients immunized with an anti-Id antibody mimicking Her-2/neu will generate sustained high titer Her-2/neu specific protective antibodies. We have used an anti-Her-2/neu murine monoclonal antibody 4D5 as the immunizing antibody (Ab1) against which monoclonal anti-Ids or Ab2s were generated in syngeneic mice. We have characterized one such anti-Id (Ab2) designated 6D12, which mimics a specific epitope of Her-2/neu as defined by Trastuzumab, and can be used as a surrogate antigen for Her-2/neu across the species barriers. Immunization of allogeneic mice or rabbits with 6D12 induced anti-anti-Id (Ab3), that specifically recognized Her-2/neu-positive tumor cells and lysed these cells in culture by antibody-dependent cellular cytotoxicity (ADCC). Monoclonal Ab3 generated in mice against 6D12 inhibited the proliferation of Her-2/neu-positive SK-BR-3 cells in vitro in a dose dependent fashion and delayed the growth of Her-2/neu transfected EL4-Her-2 cells in vivo. These data suggest the potential use of 6D12 as a vaccine for Her-2/neu-positive human cancer.

Original language	English (US)
Pages (from-to)	1916-1925
Number of pages	10
Journal	Cancer Biology and Therapy
Volume	6
Issue number	12
DOIs	https://doi.org/10.4161/cbt.6.12.4967
State	Published - Dec 2007

Bibliographical note

Funding Information:
We would like to thank Dr. Joseph D. Rosen-blatt (University of Miami, Miami, FL) for providing the EL4-Her-2 cell line. We also like to thank Mary B. Palascak and Peter Ciraolo for help in flow cytometry. This work was supported by the NIH Grant RO1 CA91878.

Keywords

Anti-idiotype antibody
Anti-tumor immunity
Breast cancer
Her-2/neu
Idiotypic cascade
Therapy
Vaccines

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.4161/cbt.6.12.4967

OpenUrl availability

Full text

Cite this

@article{32017c136f4c456db92040cc5dfe4a72,

title = "Generation of Her-2/neu vaccine utilizing idiotypic network cascade",

abstract = "Our goal is to apply an anti-idiotype (Id) antibody based vaccine approach for the treatment of Her-2/neu-positive human cancer. Amplification and/or overexpression of Her-2/neu occur in multiple human malignancies and are associated with poor prognosis. The Her-2/neu proto-oncogene is a suitable target for cancer immunotherapy. Our strategy is active specific immunotherapy in which patients immunized with an anti-Id antibody mimicking Her-2/neu will generate sustained high titer Her-2/neu specific protective antibodies. We have used an anti-Her-2/neu murine monoclonal antibody 4D5 as the immunizing antibody (Ab1) against which monoclonal anti-Ids or Ab2s were generated in syngeneic mice. We have characterized one such anti-Id (Ab2) designated 6D12, which mimics a specific epitope of Her-2/neu as defined by Trastuzumab, and can be used as a surrogate antigen for Her-2/neu across the species barriers. Immunization of allogeneic mice or rabbits with 6D12 induced anti-anti-Id (Ab3), that specifically recognized Her-2/neu-positive tumor cells and lysed these cells in culture by antibody-dependent cellular cytotoxicity (ADCC). Monoclonal Ab3 generated in mice against 6D12 inhibited the proliferation of Her-2/neu-positive SK-BR-3 cells in vitro in a dose dependent fashion and delayed the growth of Her-2/neu transfected EL4-Her-2 cells in vivo. These data suggest the potential use of 6D12 as a vaccine for Her-2/neu-positive human cancer.",

keywords = "Anti-idiotype antibody, Anti-tumor immunity, Breast cancer, Her-2/neu, Idiotypic cascade, Therapy, Vaccines",

author = "Smarajit Pal and Asim Saha and Kartik Mohanty and Palash Mallick and Chatterjee, {Sunil K.} and Foon, {Kenneth A.} and Malaya Bhattacharya-Chatterjee",

note = "Funding Information: We would like to thank Dr. Joseph D. Rosen-blatt (University of Miami, Miami, FL) for providing the EL4-Her-2 cell line. We also like to thank Mary B. Palascak and Peter Ciraolo for help in flow cytometry. This work was supported by the NIH Grant RO1 CA91878.",

year = "2007",

month = dec,

doi = "10.4161/cbt.6.12.4967",

language = "English (US)",

volume = "6",

pages = "1916--1925",

journal = "Cancer Biology and Therapy",

issn = "1538-4047",

publisher = "Landes Bioscience",

number = "12",

}

TY - JOUR

T1 - Generation of Her-2/neu vaccine utilizing idiotypic network cascade

AU - Pal, Smarajit

AU - Saha, Asim

AU - Mohanty, Kartik

AU - Mallick, Palash

AU - Chatterjee, Sunil K.

AU - Foon, Kenneth A.

AU - Bhattacharya-Chatterjee, Malaya

N1 - Funding Information: We would like to thank Dr. Joseph D. Rosen-blatt (University of Miami, Miami, FL) for providing the EL4-Her-2 cell line. We also like to thank Mary B. Palascak and Peter Ciraolo for help in flow cytometry. This work was supported by the NIH Grant RO1 CA91878.

PY - 2007/12

Y1 - 2007/12

N2 - Our goal is to apply an anti-idiotype (Id) antibody based vaccine approach for the treatment of Her-2/neu-positive human cancer. Amplification and/or overexpression of Her-2/neu occur in multiple human malignancies and are associated with poor prognosis. The Her-2/neu proto-oncogene is a suitable target for cancer immunotherapy. Our strategy is active specific immunotherapy in which patients immunized with an anti-Id antibody mimicking Her-2/neu will generate sustained high titer Her-2/neu specific protective antibodies. We have used an anti-Her-2/neu murine monoclonal antibody 4D5 as the immunizing antibody (Ab1) against which monoclonal anti-Ids or Ab2s were generated in syngeneic mice. We have characterized one such anti-Id (Ab2) designated 6D12, which mimics a specific epitope of Her-2/neu as defined by Trastuzumab, and can be used as a surrogate antigen for Her-2/neu across the species barriers. Immunization of allogeneic mice or rabbits with 6D12 induced anti-anti-Id (Ab3), that specifically recognized Her-2/neu-positive tumor cells and lysed these cells in culture by antibody-dependent cellular cytotoxicity (ADCC). Monoclonal Ab3 generated in mice against 6D12 inhibited the proliferation of Her-2/neu-positive SK-BR-3 cells in vitro in a dose dependent fashion and delayed the growth of Her-2/neu transfected EL4-Her-2 cells in vivo. These data suggest the potential use of 6D12 as a vaccine for Her-2/neu-positive human cancer.

AB - Our goal is to apply an anti-idiotype (Id) antibody based vaccine approach for the treatment of Her-2/neu-positive human cancer. Amplification and/or overexpression of Her-2/neu occur in multiple human malignancies and are associated with poor prognosis. The Her-2/neu proto-oncogene is a suitable target for cancer immunotherapy. Our strategy is active specific immunotherapy in which patients immunized with an anti-Id antibody mimicking Her-2/neu will generate sustained high titer Her-2/neu specific protective antibodies. We have used an anti-Her-2/neu murine monoclonal antibody 4D5 as the immunizing antibody (Ab1) against which monoclonal anti-Ids or Ab2s were generated in syngeneic mice. We have characterized one such anti-Id (Ab2) designated 6D12, which mimics a specific epitope of Her-2/neu as defined by Trastuzumab, and can be used as a surrogate antigen for Her-2/neu across the species barriers. Immunization of allogeneic mice or rabbits with 6D12 induced anti-anti-Id (Ab3), that specifically recognized Her-2/neu-positive tumor cells and lysed these cells in culture by antibody-dependent cellular cytotoxicity (ADCC). Monoclonal Ab3 generated in mice against 6D12 inhibited the proliferation of Her-2/neu-positive SK-BR-3 cells in vitro in a dose dependent fashion and delayed the growth of Her-2/neu transfected EL4-Her-2 cells in vivo. These data suggest the potential use of 6D12 as a vaccine for Her-2/neu-positive human cancer.

KW - Anti-idiotype antibody

KW - Anti-tumor immunity

KW - Breast cancer

KW - Her-2/neu

KW - Idiotypic cascade

KW - Therapy

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=42549162931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42549162931&partnerID=8YFLogxK

U2 - 10.4161/cbt.6.12.4967

DO - 10.4161/cbt.6.12.4967

M3 - Article

C2 - 18059165

AN - SCOPUS:42549162931

SN - 1538-4047

VL - 6

SP - 1916

EP - 1925

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

IS - 12

ER -

Generation of Her-2/neu vaccine utilizing idiotypic network cascade

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this